Compare Merck & Co., Inc. (MRK) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Merck & Co., Inc. trades at $148.11 (market cap $366.28B), while Direxion Daily FTSE China Bull 3x Shares trades at $27.31. The key difference: Merck & Co., Inc. pays a 2.29% dividend while Direxion Daily FTSE China Bull 3x Shares pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals.
| MRK | YINN | |
|---|---|---|
Market Cap | $366.28B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $156.43 | $56.62 |
52-Week Low | $77.60 | $21.45 |
Enterprise Value | $413.04B | — |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
YINN, the Direxion Daily FTSE China Bull 3x ETF, is trading at $28.05, down 7.49% with a bearish technical signal. The leveraged ETF faces pressure from mixed Chinese economic policies and U.S.-China trade tensions. Recent news highlights China's AI investment plans and export controls, creating volatility. Technical indicators show strong bearish momentum with moving averages signaling sell pressure.
The outlook remains cautious due to YINN's leveraged structure amplifying risks amid geopolitical uncertainty. While China's tech sector shows IPO momentum, the fund's inherent decay and China's economic stabilization efforts present both opportunity and significant risk for investors seeking Chinese equity exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
